Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Trial of RNA-based Malaria Vaccine BNT165e in Healthy Adults
NCT06069544Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BNT165c and BNT165d in malaria (12 arms), sponsored by BioNTech SE. Primary endpoints: Number and Percentage of Participants With Solicited Local Reactions at the Injection Site, Number and Percentage of Participants With Solicited Systemic Reactions and 3 more. Started Nov 2023; status: completed.
02
Drugs
BNT165cBNT165d
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06069544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069544.